Google the text and find it yourself. It is here. FDA news
BIOTECH NEWS STOCK REVIEW
2013 FDA Calender, Latest Clinical Trial Results And Biotech News Along With Biotech Stocks Forecast and Predictions
—FDA 2013 CALENDER AND CLINICAL TRIAL RESULTS—ALERT__BREAKING BIOTECH NEWS STOCK REVIEW BREAKS IT FIRST!_APPROVAL GRANTED_BIO-MATRIX SCIENTIFIC GROUP (BMSN) SAILS THROUGH FDA INVESTIGATIONAL NEW DRUG (IND) PROCESS, NEXT ORPHAN DRUG DESIGNATION PREDICTS BIOTECH NEWS STOCK REVIEW
Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review.
Johnny is hearing from his very reliable sources that the FDA is shortly going to release the good news that BMSN shareholders have been waiting for, APPROVAL for HemaXellerate to move on and proceed with clinical trials. Wait for official word and then enjoy the ride shareholders of BMSN, check back for more updates!
Biotech Stock Share Price Rise Or Fall Projections For Week Of February 25th To March 1st 2013.
Utilizing a unique complex Japanese based technical indicator formula that has consistently yielded a 92% success accuracy rate here are Adam and Johnny’s forecasts for the coming week, before you freak out remember these stock calls are for the entire week. In other words a stock that is rated to go up will end up higher at the end of the week than it started and a stock rated lower will see it’s share price decline at week end from where it began! Caveat, these calls are based on current technical indicators, ANY POSITIVE NEWS is likely to override these forecasts!
Dynavax (DVAX) UP
Amarantus BioScience (AMBS) UP
Bio-Matrix Scientific Group (BMSN) DOWN
Arena Pharmaceuticals (ARNA) UP
Peregrine Pharmaceuticals (PPHM) UP
Every week we publish our highly accurate calls for about 20 biotech stocks. Our selections will almost always be higher or lower at the end of the week as we forecast, check back for our weekly picks.
FDA Approval Calender 2013
About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines.
Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was instrumental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing.
Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts.
If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about.
Biotech News Stock Review Blog
What Stock Adam And Johnny Are Long On But Do Not Blog About – Read the independent, DD it will blow you away-1000% Gains Likely This Year!